Researchers got the immune-boosting results they wanted from Moderna's vaccine candidate

(Image credit: JOSEPH PREZIOSO/AFP via Getty Images)

published 14 July 2020

The results from the first phase of Moderna's coronavirus vaccine trial are out, and the promising findings are in line with some early data from the study released in May.

The study, published Tuesday in The New England Journal of Medicine, found the experimental mRNA vaccine — which requires two doses a month apart — induced coronavirus immune responses in all 45 participants, just as scientists had hoped. There were some mild side effects, including fatigue, chills, and fevers, but The Associated Press notes those aren't uncommon with other vaccines, and there have been no major safety concerns.

Moderna will begin its final step at the end of July, a 30,000-person study to prove if the shots are strong enough to protect people from the virus. While the first phase does indicate the vaccine produces antibodies geared toward fighting off the virus, it's less clear if the levels of antibodies are enough to actually fend off infection. Read the full results of the study at The New England Journal of Medicine, as well as more context at The Associated Press.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE

https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Explore More

Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.

Subscribe to The Week

Sign up for The Week's Free Newsletters

Sign up for Today's Best Articles in your inbox